Recruiting × Granulocyte Colony-Stimulating Factor × 1 year × Clear all Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Phase 2 Recruiting
30 enrolled
waveLINE-003
Phase 2/3 Recruiting
290 enrolled
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Phase 1 Recruiting
60 enrolled
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Recruiting
116 enrolled
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Phase 1 Recruiting
120 enrolled
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
Phase 1 Recruiting
20 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Phase 2 Recruiting
160 enrolled
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Phase 1 Recruiting
30 enrolled
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
Phase 2 Recruiting
33 enrolled
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Phase 2 Recruiting
40 enrolled
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Phase 1/2 Recruiting
63 enrolled
RADAR
Phase 3 Recruiting
1,042 enrolled
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
Phase 2 Recruiting
52 enrolled
ABCD-NK
Phase 1/2 Recruiting
68 enrolled
REaCT-OGF
Phase 4 Recruiting
242 enrolled
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Phase 2 Recruiting
52 enrolled
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
Phase 1/2 Recruiting
25 enrolled
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Phase 1 Recruiting
60 enrolled
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
Phase 3 Recruiting
99 enrolled
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
171 enrolled
EPOCH
Recruiting
45 enrolled
HSCT
Phase 2 Recruiting
100 enrolled
RAFA
Phase 2 Recruiting
70 enrolled
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Phase 1/2 Recruiting
36 enrolled
GM-CSF With Post-Transplant Cyclophosphamide
Phase 2 Recruiting
38 enrolled
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
Phase 2 Recruiting
12 enrolled
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 Recruiting
270 enrolled
G-CSF After Chemo-radiation in Patients With Glioblastoma
Phase 2 Recruiting
60 enrolled
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
Phase 2 Recruiting
39 enrolled
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Phase 3 Recruiting
324 enrolled